sobuzoxane has been researched along with Experimental Neoplasms in 2 studies
sobuzoxane: used in treatment of leukemia L1210
| Excerpt | Relevance | Reference |
|---|---|---|
| " The LD50 of DOX administered i." | 1.30 | MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. ( Maehara, Y; Sugimachi, K; Yoshida, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshida, M | 1 |
| Maehara, Y | 1 |
| Sugimachi, K | 1 |
| Narita, T | 1 |
| Koide, Y | 1 |
| Yaguchi, S | 1 |
| Kimura, S | 1 |
| Izumisawa, Y | 1 |
| Takase, M | 1 |
| Inaba, M | 1 |
| Tsukagoshi, S | 1 |
2 other studies available for sobuzoxane and Experimental Neoplasms
| Article | Year |
|---|---|
MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1999 |
Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Survival; Cells, | 1991 |